Literature DB >> 16338597

Asthma-related resource use and cost by GINA classification of severity in three European countries.

E Van Ganse1, L Antonicelli, Q Zhang, L Laforest, D D Yin, G Nocea, V Sazonov Kocevar.   

Abstract

BACKGROUND: This study assessed the relationship between asthma burden and asthma severity in France, Italy, and Spain.
METHODS: Adult asthmatics, 18-55 years of age, completed a questionnaire while visiting a respiratory physician in 1998 and 1999. Asthma severity was categorized by physicians as intermittent, mild persistent, moderate persistent, or severe persistent according to Global Initiative for Asthma (GINA) guidelines.
RESULTS: Totals of 282 patients in France, 500 in Italy, and 296 in Spain entered the study. There were few differences between the three countries in the asthma symptom burden. Most patients with persistent asthma had used inhaled corticosteroids in the previous 14 days. Unexpectedly, 35% (Italy) to 83% (Spain) of patients with intermittent asthma also had used inhaled corticosteroids. In Spain, visits to the emergency department were more frequent (OR 7.0, 95% CI 4.9-10.0 with Italy as reference) and the costs of emergency care in all asthma severity categories were up to 10 times higher than in Italy and France. The frequency of hospitalizations did not differ systematically between the three countries.
CONCLUSIONS: Inadequate control of asthma symptoms among patients with severe persistent asthma could not be entirely explained by under-prescribing of asthma medications. The use of inhaled corticosteroids by patients with intermittent asthma might reflect misclassification of asthma severity, possibly due to difficulty in interpreting the GINA guidelines. The relatively high cost of emergency care in Spain does not appear to be related to greater asthma severity or poorer symptom control, but may be a feature of the Spanish health care system.

Entities:  

Mesh:

Year:  2005        PMID: 16338597     DOI: 10.1016/j.rmed.2005.03.041

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  10 in total

1.  Suggestive association between variants in IL1RAPL and asthma symptoms in Latin American children.

Authors:  Cintia Rodrigues Marques; Gustavo No Costa; Thiago Magalhães da Silva; Pablo Oliveira; Alvaro A Cruz; Neuza Maria Alcantara-Neves; Rosemeire L Fiaccone; Bernardo L Horta; Fernando Pires Hartwig; Esteban G Burchard; Maria Pino-Yanes; Laura C Rodrigues; Maria Fernanda Lima-Costa; Alexandre C Pereira; Mateus H Gouveia; Hanaisa P Sant Anna; Eduardo Tarazona-Santos; Maurício Lima Barreto; Camila Alexandrina Figueiredo
Journal:  Eur J Hum Genet       Date:  2017-01-25       Impact factor: 4.246

2.  Cost-effectiveness and cost-utility of beclomethasone/formoterol versus fluticasone propionate/salmeterol in patients with moderate to severe asthma.

Authors:  Simone Gerzeli; Carla Rognoni; Silvana Quaglini; Maria Caterina Cavallo; Giovanni Cremonesi; Alberto Papi
Journal:  Clin Drug Investig       Date:  2012-04-01       Impact factor: 2.859

3.  Lower Use of Biologics for the Treatment of Asthma in Publicly Insured Individuals.

Authors:  Ayobami T Akenroye; James Heyward; Corinne Keet; G Caleb Alexander
Journal:  J Allergy Clin Immunol Pract       Date:  2021-02-06

4.  Prescription of antibiotics and anxiolytics/hypnotics to asthmatic patients in general practice: a cross-sectional study based on French and Italian prescribing data.

Authors:  David Darmon; Laurent Laforest; Eric Van Ganse; Ferdinando Petrazzuoli; Chris van Weel; Laurent Letrilliart
Journal:  BMC Fam Pract       Date:  2015-02-06       Impact factor: 2.497

5.  Using an electronic medical record (EMR) to conduct clinical trials: Salford Lung Study feasibility.

Authors:  Hanaa F Elkhenini; Kourtney J Davis; Norman D Stein; John P New; Mark R Delderfield; Martin Gibson; Jorgen Vestbo; Ashley Woodcock; Nawar Diar Bakerly
Journal:  BMC Med Inform Decis Mak       Date:  2015-02-07       Impact factor: 2.796

6.  Enhancing the use of Asthma and COPD Assessment Tools in Balearic Primary Care (ACATIB): a region-wide cluster-controlled implementation trial.

Authors:  Miguel Román-Rodríguez; Marina Garcia Pardo; Lucia Gorreto López; Ana Uréndez Ruiz; Job F M van Boven
Journal:  NPJ Prim Care Respir Med       Date:  2016-03-10       Impact factor: 2.871

7.  Comorbidities are associated with different features of severe asthma.

Authors:  Federica Novelli; Elena Bacci; Manuela Latorre; Veronica Seccia; Maria Laura Bartoli; Silvana Cianchetti; Federico Lorenzo Dente; Antonella Di Franco; Alessandro Celi; Pierluigi Paggiaro
Journal:  Clin Mol Allergy       Date:  2018-12-03

8.  Prevalence of severe asthma according to the drug regulatory agency perspective: An Italian experience.

Authors:  A Vianello; M Caminati; M Andretta; A M Menti; S Tognella; G Senna; L Degli Esposti
Journal:  World Allergy Organ J       Date:  2019-05-10       Impact factor: 4.084

9.  Early responders within seven days of dupilumab treatment for severe asthma evaluated by patient-reported outcome: a pilot study.

Authors:  Nozomi Tani; Nobutaka Kataoka; Yusuke Kunimatsu; Yusuke Tachibana; Takumi Sugimoto; Izumi Sato; Yuri Ogura; Kazuki Hirose; Takayuki Takeda
Journal:  Multidiscip Respir Med       Date:  2021-03-17

10.  Factors influencing asthma control: results of a real-life prospective observational asthma inhaler treatment (ASIT) study.

Authors:  Füsun Yıldız
Journal:  J Asthma Allergy       Date:  2013-07-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.